24/7 Market News Snapshot 08 October, 2024 – Bio-Path Holdings Inc (NASDAQ:BPTH)

October 8, 2024

DENVER, Colo., 08 October, 2024 (247marketnews.com) – (NASDAQ:BPTH) are discussed in this article.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) is currently experiencing a significant surge in pre-market trading, with shares rising by an impressive 28.98% to $1.098 from the previous close of $0.851, reflecting strong investor enthusiasm. With a trading volume exceeding 1.39 million shares, the market’s positive sentiment speaks to the heightened interest in the company, particularly as it advances its innovative capabilities in biotechnology.

The company is pioneering a new therapeutic program centered on BP1001-A, leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to target obesity and related metabolic disorders. This initiative represents a major expansion of Bio-Path’s technological applications beyond oncology, marking the first endeavor aimed specifically at non-cancer conditions amid the global obesity epidemic that contributes to severe health challenges such as Type 2 diabetes. Peter H. Nielsen, President and CEO, expressed optimism about the potential of BP1001-A to address insulin resistance, a critical factor in obesity and metabolic disorders, with plans to initiate IND-enabling testing by the fourth quarter of 2024.

Concurrently, Bio-Path has achieved a significant milestone by completing the enrollment of the third dosing cohort in its ongoing Phase 1/1b clinical trial for BP1002, which targets patients with relapsed or refractory acute myeloid leukemia (AML). This rapid enrollment underscores the urgent need for innovative treatment options in this challenging patient population.

With a dual focus on advancing solutions for both metabolic diseases and oncology, Bio-Path is well-positioned at the forefront of biopharmaceutical innovation. The anticipated preclinical studies for BP1001-A are expected to provide essential insights into its potential therapeutic effectiveness, ultimately advancing the company’s mission to enhance patient care through cutting-edge treatment options.

Related news for (BPTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.